In a preclinical model of CD24+ solid tumours, the blockade of CD24‐Siglec‐10 interaction with anti‐CD24 mAb showed an increase in TAMs‐associated phagocytosis in vitro and TAMs‐dependent reduction of tumour growth and improvement of survival in vivo.14 This evidence concerns the gene CD24 and neoplasm.